In a reversal of two decades of medical reports, a Mayo Clinic study finds the frequency of nerve damage called diabetic polyneuropathy is similar in prediabetic patients and healthy people.

New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is diagnosed. Eduardo De Sousa, M.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and director of the Electrodiagnostic Neuromuscular Lab at JHN

The U.S. Food and Drug Administration approved an immune globulin product called Gamunex for treatment of chronic inflammatory demyelinating polyneuropathy. The disease is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.

SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today the publication of Phase 3 data of its lead product candidate, NGX-4010, in the journal Neurology.

SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the presentation of encouraging Phase 1b clinical data from its ZFP Therapeutic(TM) program at the 68th Scientific Sessions of the American Diabetes Association (ADA).